{"transactions":[{"id":1249706,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-02-24T21:15:05.000Z","date":"2025-02-21","kind":"sale","planned":false,"acquired":false,"shares":106,"price":10.0758,"value":1068.0348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":6517,"source":{"system":"sec-edgar","filing":"0000950170-25-025630","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025025630/ownership.xml","form_type":"4"}},{"id":1294528,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-27T21:16:31.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":5,"price":9.9402,"value":49.701,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":6623,"source":{"system":"sec-edgar","filing":"0000950170-25-009205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009205/ownership.xml","form_type":"4"}},{"id":1294527,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-27T21:16:31.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":47,"price":9.4538,"value":444.3286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":6628,"source":{"system":"sec-edgar","filing":"0000950170-25-009205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009205/ownership.xml","form_type":"4"}},{"id":1304350,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-01-13T21:15:08.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":409,"price":0.4401,"value":180.0009,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":153541,"source":{"system":"sec-edgar","filing":"0000950170-25-004834","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025004834/ownership.xml","form_type":"4"}},{"id":1335751,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-12-11T22:07:44.000Z","date":"2024-12-11","kind":"gift","planned":false,"acquired":true,"shares":57549,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 11, 2024, the Reporting Person transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":346348,"source":{"system":"sec-edgar","filing":"0000950170-24-135443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024135443/ownership.xml","form_type":"4"}},{"id":1335750,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-12-11T22:07:44.000Z","date":"2024-12-11","kind":"gift","planned":false,"acquired":false,"shares":57549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 11, 2024, the Reporting Person transferred 57,549 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":153950,"source":{"system":"sec-edgar","filing":"0000950170-24-135443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024135443/ownership.xml","form_type":"4"}},{"id":1357308,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-11-20T21:15:05.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":432,"price":0.5485,"value":236.952,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":211499,"source":{"system":"sec-edgar","filing":"0000950170-24-129258","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024129258/ownership.xml","form_type":"4"}},{"id":1374289,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-11-06T21:15:12.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":2272,"price":0.8649,"value":1965.0528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":211931,"source":{"system":"sec-edgar","filing":"0000950170-24-122335","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024122335/ownership.xml","form_type":"4"}},{"id":1382393,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:02.000Z","date":"2024-10-22","kind":"sale","planned":false,"acquired":false,"shares":766,"price":0.7678,"value":588.1348,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":214203,"source":{"system":"sec-edgar","filing":"0000950170-24-116644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116644/ownership.xml","form_type":"4"}},{"id":1382392,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:02.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":635,"price":0.779,"value":494.665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":214969,"source":{"system":"sec-edgar","filing":"0000950170-24-116644","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116644/ownership.xml","form_type":"4"}},{"id":1390804,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-10-04T20:15:06.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":377,"price":0.8148,"value":307.1796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":215604,"source":{"system":"sec-edgar","filing":"0000950170-24-112913","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024112913/ownership.xml","form_type":"4"}},{"id":1427714,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-20T20:15:05.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":422,"price":0.7595,"value":320.509,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":215981,"source":{"system":"sec-edgar","filing":"0000950170-24-099106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024099106/ownership.xml","form_type":"4"}},{"id":1438843,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-07T20:15:06.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":2323,"price":0.7348,"value":1706.9404,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":216403,"source":{"system":"sec-edgar","filing":"0000950170-24-092808","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024092808/ownership.xml","form_type":"4"}},{"id":1449960,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-07-23T20:25:37.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":757,"price":0.7392,"value":559.5744,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":218726,"source":{"system":"sec-edgar","filing":"0000950170-24-085658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085658/ownership.xml","form_type":"4"}},{"id":1449959,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-07-23T20:25:37.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":634,"price":0.7501,"value":475.5634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":219483,"source":{"system":"sec-edgar","filing":"0000950170-24-085658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085658/ownership.xml","form_type":"4"}},{"id":1460126,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-07-03T20:14:49.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":379,"price":0.72,"value":272.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":220117,"source":{"system":"sec-edgar","filing":"0000950170-24-081519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024081519/ownership.xml","form_type":"4"}},{"id":1507233,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-05-21T20:33:25.000Z","date":"2024-05-17","kind":"sale","planned":false,"acquired":false,"shares":420,"price":0.7493,"value":314.706,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":220496,"source":{"system":"sec-edgar","filing":"0000950170-24-062977","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024062977/ownership.xml","form_type":"4"}},{"id":1524813,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-05-07T20:15:26.000Z","date":"2024-05-03","kind":"sale","planned":false,"acquired":false,"shares":2311,"price":0.796,"value":1839.556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":220916,"source":{"system":"sec-edgar","filing":"0000950170-24-054509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024054509/ownership.xml","form_type":"4"}},{"id":1536901,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-04-23T20:15:18.000Z","date":"2024-04-22","kind":"sale","planned":false,"acquired":false,"shares":757,"price":0.75,"value":567.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":223227,"source":{"system":"sec-edgar","filing":"0000950170-24-046907","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024046907/ownership.xml","form_type":"4"}},{"id":1536900,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-04-23T20:15:18.000Z","date":"2024-04-19","kind":"sale","planned":false,"acquired":false,"shares":626,"price":0.7506,"value":469.8756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":223984,"source":{"system":"sec-edgar","filing":"0000950170-24-046907","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024046907/ownership.xml","form_type":"4"}},{"id":1547826,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-04-04T20:15:21.000Z","date":"2024-04-02","kind":"sale","planned":false,"acquired":false,"shares":368,"price":0.772,"value":284.096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":224610,"source":{"system":"sec-edgar","filing":"0000950170-24-041809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024041809/ownership.xml","form_type":"4"}},{"id":1625494,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-02-22T21:16:21.000Z","date":"2024-02-20","kind":"sale","planned":false,"acquired":false,"shares":385,"price":0.6952,"value":267.652,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":224978,"source":{"system":"sec-edgar","filing":"0000950170-24-018786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024018786/ownership.xml","form_type":"4"}},{"id":1656831,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-02-06T21:40:19.000Z","date":"2024-02-05","kind":"sale","planned":false,"acquired":false,"shares":8869,"price":0.67,"value":5942.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":225363,"source":{"system":"sec-edgar","filing":"0000950170-24-011771","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024011771/ownership.xml","form_type":"4"}},{"id":1670972,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-01-25T21:15:09.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":1302,"price":0.6708,"value":873.3816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6797. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":234232,"source":{"system":"sec-edgar","filing":"0000950170-24-007403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024007403/ownership.xml","form_type":"4"}},{"id":1684271,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-01-08T21:15:22.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":424,"price":0.639,"value":270.936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":235534,"source":{"system":"sec-edgar","filing":"0000950170-24-002937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024002937/ownership.xml","form_type":"4"}},{"id":2033137,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:00:29.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":497844,"derivative":{"exercise_price":6.65,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001209191-23-006992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006992/doc4.xml","form_type":"4"}},{"id":2033136,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-02-03T22:00:29.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":235958,"source":{"system":"sec-edgar","filing":"0001209191-23-006992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006992/doc4.xml","form_type":"4"}},{"id":2048744,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-01-24T00:00:21.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":541,"price":5.1438,"value":2782.7958,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":148458,"source":{"system":"sec-edgar","filing":"0001209191-23-004501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123004501/doc4.xml","form_type":"4"}},{"id":2048743,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-01-24T00:00:21.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":2032,"price":5.0777,"value":10317.8864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":148999,"source":{"system":"sec-edgar","filing":"0001209191-23-004501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123004501/doc4.xml","form_type":"4"}},{"id":2048742,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-01-24T00:00:21.000Z","date":"2022-12-02","kind":"gift","acquired":true,"shares":98346,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2022, the Reporting Person transferred 98,346 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":288799,"source":{"system":"sec-edgar","filing":"0001209191-23-004501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123004501/doc4.xml","form_type":"4"}},{"id":2048741,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2023-01-24T00:00:21.000Z","date":"2022-12-02","kind":"gift","acquired":false,"shares":98346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 2, 2022, the Reporting Person transferred 98,346 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":151031,"source":{"system":"sec-edgar","filing":"0001209191-23-004501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123004501/doc4.xml","form_type":"4"}},{"id":2114645,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-11-16T22:10:33.000Z","date":"2022-11-14","kind":"sale","acquired":false,"shares":2358,"price":8.9135,"value":21018.033,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.90 to $8.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":190453,"source":{"system":"sec-edgar","filing":"0000899243-22-036018","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322036018/doc4.xml","form_type":"4"}},{"id":2131654,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-10-26T20:15:48.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":553,"price":9.3607,"value":5176.4671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":249377,"source":{"system":"sec-edgar","filing":"0000899243-22-034265","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034265/doc4a.xml","form_type":"4/A","original_submission_date":"2022-10-24"}},{"id":2133011,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-10-24T22:24:34.000Z","date":"2022-10-19","kind":"sale","acquired":false,"shares":553,"price":9.3607,"value":5176.4671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":249377,"source":{"system":"sec-edgar","filing":"0000899243-22-034056","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034056/doc4.xml","form_type":"4"}},{"id":2181869,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-08-17T22:02:59.000Z","date":"2022-08-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":249930,"source":{"system":"sec-edgar","filing":"0000899243-22-029058","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322029058/doc4.xml","form_type":"4"}},{"id":2212083,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T11:30:25.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":26000,"derivative":{"exercise_price":4.13,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0000899243-22-025235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025235/doc4.xml","form_type":"4"}},{"id":2212082,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-07-06T11:30:25.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,623 shares acquired under the AlloVir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022."}],"balance_after":234930,"source":{"system":"sec-edgar","filing":"0000899243-22-025235","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025235/doc4.xml","form_type":"4"}},{"id":2308499,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-04T20:23:32.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":56744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":56744,"derivative":{"exercise_price":9.15,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":56744},"source":{"system":"sec-edgar","filing":"0000899243-22-013334","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322013334/doc4.xml","form_type":"4"}},{"id":2308498,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2022-04-04T20:23:32.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":23256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":217307,"source":{"system":"sec-edgar","filing":"0000899243-22-013334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322013334/doc4.xml","form_type":"4"}},{"id":2814234,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-03-04T01:35:16.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":2200,"price":39.1398,"value":86107.56,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.93 to $39.475. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":192811,"source":{"system":"sec-edgar","filing":"0001209191-21-017529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017529/doc4.xml","form_type":"4"}},{"id":2814233,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-03-04T01:35:16.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":3800,"price":38.5768,"value":146591.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 4, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.92 to $38.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":195011,"source":{"system":"sec-edgar","filing":"0001209191-21-017529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121017529/doc4.xml","form_type":"4"}},{"id":2900863,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T00:24:28.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":42.15,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0000899243-21-002759","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002759/doc4.xml","form_type":"4"}},{"id":2900862,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-01-22T00:24:28.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":194051,"source":{"system":"sec-edgar","filing":"0000899243-21-002759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002759/doc4.xml","form_type":"4"}},{"id":2900861,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-01-22T00:24:28.000Z","date":"2020-12-01","kind":"gift","acquired":true,"shares":41514,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":198811,"source":{"system":"sec-edgar","filing":"0000899243-21-002759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002759/doc4.xml","form_type":"4"}},{"id":2900860,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2021-01-22T00:24:28.000Z","date":"2020-12-01","kind":"gift","acquired":false,"shares":41514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 1, 2020, the Reporting Person transferred 41,514 shares to The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":166051,"source":{"system":"sec-edgar","filing":"0000899243-21-002759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002759/doc4.xml","form_type":"4"}},{"id":3066017,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-06T10:11:44.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":48819,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":32759},"source":{"system":"sec-edgar","filing":"0000899243-20-021599","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021599/doc4.xml","form_type":"4"}},{"id":3066016,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2020-08-06T10:11:44.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":32759,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":32759,"source":{"system":"sec-edgar","filing":"0000899243-20-021599","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021599/doc4.xml","form_type":"4"}},{"id":3072597,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:42:24.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":200600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":200600,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":200600},"source":{"system":"sec-edgar","filing":"0000899243-20-020926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020926/doc4.xml","form_type":"4"}},{"id":4415431,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-03-01T19:45:46.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":8700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Stock option award under 2004 Incentive Plan.  25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years."}],"balance_after":8700,"derivative":{"exercise_price":131.25,"exercise_date":"2018-02-28","expiration_date":"2027-02-28","underlying":"Common Stock, par value $.0001 per share","underlying_shares":8700},"source":{"system":"sec-edgar","filing":"0000899866-17-000058","document":"wf-form4_148841553225370.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000058/wf-form4_148841553225370.xml","form_type":"4"}},{"id":4415430,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:46.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Award of Restricted Stock Units under the 2004 Incentive Plan.  25% vests on each anniversary of the grant date."}],"balance_after":19284,"source":{"system":"sec-edgar","filing":"0000899866-17-000058","document":"wf-form4_148841553225370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000058/wf-form4_148841553225370.xml","form_type":"4"}},{"id":4415429,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:46.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":330,"price":131.7,"value":43461.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":14884,"source":{"system":"sec-edgar","filing":"0000899866-17-000058","document":"wf-form4_148841553225370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000058/wf-form4_148841553225370.xml","form_type":"4"}},{"id":4415428,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-03-01T19:45:46.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":260,"price":131.2,"value":34112.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":15214,"source":{"system":"sec-edgar","filing":"0000899866-17-000058","document":"wf-form4_148841553225370.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000058/wf-form4_148841553225370.xml","form_type":"4"}},{"id":4462468,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:39:44.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":9,"price":126.95,"value":1142.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":15474,"source":{"system":"sec-edgar","filing":"0000899866-17-000027","document":"wf-form4_148658996992757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000027/wf-form4_148658996992757.xml","form_type":"4"}},{"id":4462467,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-02-08T16:39:44.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":1036,"price":125.69,"value":130214.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $125.00 - $125.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":15483,"source":{"system":"sec-edgar","filing":"0000899866-17-000027","document":"wf-form4_148658996992757.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000027/wf-form4_148658996992757.xml","form_type":"4"}},{"id":4607099,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":82880,"kind":"person","name":"Miller Edward","position":1,"cik":"0001619252","reported_name":"Miller Edward","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Compliance Officer"}}],"security":"Common Stock, par value $.0001 per share","published_at":"2016-09-09T18:23:35.000Z","date":"2016-09-09","kind":"sale","acquired":false,"shares":367,"price":128.32,"value":47093.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $128.00 - $128.99.  The price reported in this column reflects the weighted average sales price.  Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price."}],"balance_after":16519,"source":{"system":"sec-edgar","filing":"0000899866-16-000353","document":"wf-form4_147345980329358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986616000353/wf-form4_147345980329358.xml","form_type":"4"}}]}